CDKN2A Gene Function
Cyclin Dependent Kinase Inhibitor 2A
Overview
CDKN2A encodes two distinct tumor suppressors: p16INK4a (inhibits CDK4/6) and p14ARF (stabilizes p53 by inhibiting MDM2). Deletion or silencing of this locus is one of the most frequent alterations in human cancer.
Molecular Mechanism
Mechanism Summary
CDKN2A uniquely encodes two structurally unrelated tumour suppressors from overlapping reading frames: p16INK4a (inhibits CDK4/6 → pRb pathway) and p14ARF (sequesters MDM2 → p53 pathway). A single deletion disables both major tumour suppressor circuits simultaneously.
Step-by-Step Mechanism
Without CDK4/6 activity, pRb remains hypophosphorylated and bound to E2F transcription factors, maintaining G1 cell cycle arrest. p16-imposed G1 arrest is a key effector mechanism of oncogene-induced senescence.
Stabilised p53 activates p21 (CDKN1A) for CDK2 inhibition, reinforcing G1 arrest initiated by p16–CDK4/6 inhibition. The combined p16+ARF deletion therefore eliminates both G1 arrest mechanisms simultaneously.
CpG island hypermethylation of the p16INK4a promoter silences CDKN2A epigenetically in many cancers without DNA sequence mutation. This is one of the most common epigenetic alterations in human carcinogenesis and is reversible by DNMT inhibitors.
Upstream Regulators
Transcriptionally activates p14ARF in response to pRb loss; ARF-p53-mediated apoptosis acts as a safeguard against unchecked E2F
Induce p14ARF expression as part of oncogene-induced senescence programme
CpG island hypermethylation silences p16INK4a in many cancers
Downstream Targets
Kinase inhibition → pRb hypophosphorylation → E2F repression → G1 arrest
Nucleolar sequestration → p53 stabilisation → G1 arrest or apoptosis
Key Post-Translational Modifications
Transcriptional silencing; functionally equivalent to deletion
ARF degradation; limits p53 stabilisation amplitude
Disease Mechanism
CDKN2A is homozygously deleted in ~50% of melanomas and pancreatic cancers, ~30% of glioblastomas, and frequently in NSCLC, mesothelioma, and lymphoma. The concurrent disabling of both the pRb and p53 pathways through a single genomic event explains its extraordinary selective advantage in cancer. Germline CDKN2A mutations cause familial atypical mole and melanoma (FAMM) syndrome with markedly elevated pancreatic cancer risk.
Database References
Key Pathways
- ·Cell cycle G1/S checkpoint
- ·p53 pathway (via ARF)
- ·RB pathway (via p16)
Disease Associations
- ·Melanoma
- ·Pancreatic cancer
- ·Familial atypical mole melanoma syndrome
Research Activity
CDKN2A is an actively studied target: about 40+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track CDKN2A trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About CDKN2A
What does CDKN2A encode and why is it unusual?
CDKN2A is unique in encoding two completely separate tumor suppressor proteins from overlapping reading frames: p16INK4a, which inhibits CDK4/CDK6 to block pRb phosphorylation, and p14ARF, which sequesters MDM2 to stabilise p53. A single CDKN2A deletion therefore simultaneously disables both the RB and p53 pathways.
Why is CDKN2A deleted so often in cancer?
Simultaneous inactivation of both p53 and pRb tumour suppressor pathways through deletion of a single chromosomal locus provides an enormous selective advantage. CDKN2A is homozygously deleted in ~50% of melanomas, ~30% of glioblastomas, and ~90% of pancreatic cancers — making it the most frequently deleted locus in cancer.
What is p16 methylation?
p16INK4a (encoded by CDKN2A) is silenced by promoter CpG island hypermethylation in a wide range of cancers and even in normal ageing tissues and precancerous fields. This epigenetic silencing is one of the most common alterations in human cancer and is detectable in liquid biopsies.